Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

Lung cancer leads global cancer mortality, and non-small-cell variants make up more than 80% of cases. Immune checkpoint inhibitors have transformed therapy yet help only 27–45% of recipients.

9 out of 51 in the nation for lung cancer screening at 20.0%, and among the better in the U.S. Lung cancer screening with annual low-dose CT scans for those at high risk can reduce the lung cancer ...

Globally, more than 50% of women diagnosed with lung cancer are non-smokers, compared to 15% to 20% of men.Meanwhile, an estimated 57% of Asian-American women diagnosed with lung cancer have never ...

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new research published at the ATS 2025 International Conference.

Despite years of warnings and a mountain of scientific evidence linking smoking to lung cancer, there remains one confounding question: Why do some smokers. Skip to content. News; ...

I was a runner and ‘never smoker’ — then I got diagnosed with lung cancer at 28 By . Tracy Swartz. Published May 16, 2025, 6:00 a.m. ET. Deep breath!

The primary outcome was an increased risk for lung cancer associated with GERD. The analysis included 10 studies with at least 2,302,272 participants, with 90% of the studies using international ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...